APIKLOT Apixaban Antithrombotic Agent Film Coated Tablet 5mg Direct Factor XA Inhibitor Sold Per Piece [PRESCRIPTION REQUIRED]

APIXABAN
5 mg FILM COATED TABLET
ANTITHROMBOTIC (DIRECT FACTOR Xa INHIBITOR)

Origin

PHILIPPINES

Product Usage

Prevention of VTE (VTEp): elective hip or knee replacement surgery: The recommended dose of Apixaban is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. *Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window. Prevention of stroke and systemic embolism in patients with AF: NVAF: *The recommended dose of Apixaban is 5 mg taken orally twice daily. *Age, body weight, serum creatinine: In patients with at least 2 of the following characteristics, age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL(133 micromole/L), the recommended dose of Apixaban is 2.5 mg twice daily. Renal Impairment *Prevention of VTE in surgical patients: Elective hip or knee replacement surgery: No dose adjustment is necessary in patients with mild, moderate or severe (creatinine clearance 15-29 mL/min) renal impairment. Because there is limited clinical experience in patients with creatinine clearance <15 mL/min and no data in patients undergoing dialysis, Apixaban is not recommended in these patients. *Prevention of stroke and systemic embolism in patients with AF: NVAF: No dose adjustment is recommended in patients with creatinine clearance 15 to 29 mL/min, except as described in Recommended Dosage: Prevention of stroke and systemic embolism in patients with AF: NVAF previously. Because there is no clinical experience in patients with creatinine clearance <15 mL/min, a dosing recommendation cannot be provided. There are no data in patients undergoing dialysis, therefore, Apixaban is not recommended in these patients. * Treatment of VTE: No dose adjustment is necessary in patients with mild, moderate, or severe (creatinine clearance 15-29 mL/min) renal impairment. Because there is limited clinical experience in patients with creatinine clearance <15 mL/min and no data in patients undergoing dialysis, Apixaban is not recommended in these patients.

Ingredients

Apixaban 5 mg

Width

7.9

Height

2.7

Depth

5.8